---
title: "Humacyte - CW27 | 10-Q: FY2025 Q1 Revenue: USD 517 K"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/240063091.md"
datetime: "2025-05-13T21:13:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/240063091.md)
  - [en](https://longbridge.com/en/news/240063091.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/240063091.md)
---

# Humacyte - CW27 | 10-Q: FY2025 Q1 Revenue: USD 517 K

Revenue: As of FY2025 Q1, the actual value is USD 517 K.

EPS: As of FY2025 Q1, the actual value is USD 0.28.

### Segment Revenue

-   **Product Revenue, Net**: $147,000 for the three months ended March 31, 2025.
-   **Contract Revenue**: $370,000 for the three months ended March 31, 2025.

### Operational Metrics

-   **Net Income**: $39,139,000 for the three months ended March 31, 2025, compared to a net loss of $31,896,000 for the same period in 2024.
-   **Loss from Operations**: - $23,184,000 for the three months ended March 31, 2025, compared to - $26,578,000 for the same period in 2024.
-   **Research and Development Expenses**: $15,418,000 for the three months ended March 31, 2025, a decrease from $21,264,000 for the same period in 2024.
-   **Selling, General and Administrative Expenses**: $8,136,000 for the three months ended March 31, 2025, an increase from $5,314,000 for the same period in 2024.

### Cash Flow

-   **Net Cash Used in Operating Activities**: - $28,601,000 for the three months ended March 31, 2025, compared to - $27,347,000 for the same period in 2024.
-   **Net Cash Used in Investing Activities**: - $228,000 for the three months ended March 31, 2025, compared to - $391,000 for the same period in 2024.
-   **Net Cash Provided by Financing Activities**: $46,739,000 for the three months ended March 31, 2025, compared to $62,795,000 for the same period in 2024.

### Unique Metrics

-   **Change in Fair Value of Contingent Earnout Liability**: $49,731,000 gain for the three months ended March 31, 2025, compared to a - $4,593,000 loss for the same period in 2024.
-   **Change in Fair Value of Derivatives**: $14,930,000 gain for the three months ended March 31, 2025, compared to a $60,000 gain for the same period in 2024.

### Future Outlook and Strategy

-   **Core Business Focus**: The company plans to commercialize Symvess in the U.S. for vascular trauma and, if approved, in AV access for hemodialysis. It aims to obtain marketing approval for its 6 millimeter ATEV in additional indications and scale its manufacturing facility to meet market demand.
-   **Non-Core Business**: The company is exploring applications of its technology across a broad range of markets and indications, including the development of urinary conduit, trachea, esophagus, and other novel cell delivery systems.
-   **Priority**: The company estimates savings from workforce and other operating cost reductions, and reduced capital expenditures, totaling approximately $13.8 million in 2025 and up to approximately $38.0 million in 2026.

### Related Stocks

- [HUMAW.US](https://longbridge.com/en/quote/HUMAW.US.md)

## Related News & Research

- [3 Low-Cost ETFs For Investors Seeking to Check Out Walmart Ahead of Q2 Earnings – GXPS, FSTA,TRUO.](https://longbridge.com/en/news/296381462.md)
- [Interactive Brokers Is Holding $930 Billion of Customer Money. Here's What That Earns at Today's Rates.](https://longbridge.com/en/news/296319893.md)
- [Why Are Nebius Shares Trading Lower On Wednesday?](https://longbridge.com/en/news/296383504.md)
- [PPS&V Asset Management Consultants Inc. Has $7.63 Million Position in Apple Inc. $AAPL](https://longbridge.com/en/news/296327659.md)
- [Levin Capital Strategies L.P. Buys 12,303 Shares of McDonald's Corporation $MCD](https://longbridge.com/en/news/296329001.md)